Literature DB >> 20132258

Lyme borreliosis: clinical case definitions for diagnosis and management in Europe.

G Stanek1, V Fingerle, K-P Hunfeld, B Jaulhac, R Kaiser, A Krause, W Kristoferitsch, S O'Connell, K Ornstein, F Strle, J Gray.   

Abstract

Lyme borreliosis, caused by spirochaetes of the Borrelia burgdorferi genospecies complex, is the most commonly reported tick-borne infection in Europe and North America. The non-specific nature of many of its clinical manifestations presents a diagnostic challenge and concise case definitions are essential for its satisfactory management. Lyme borreliosis is very similar in Europe and North America but the greater variety of genospecies in Europe leads to some important differences in clinical presentation. These new case definitions for European Lyme borreliosis emphasise recognition of clinical manifestations supported by relevant laboratory criteria and may be used in a clinical setting and also for epidemiological investigations.
© 2010 The Authors. Journal Compilation © 2010 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Year:  2011        PMID: 20132258     DOI: 10.1111/j.1469-0691.2010.03175.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  150 in total

1.  Lyme neuroborreliosis and bird populations in northern Europe.

Authors:  Atle Mysterud; Dieter J A Heylen; Erik Matthysen; Aïda Lopez Garcia; Solveig Jore; Hildegunn Viljugrein
Journal:  Proc Biol Sci       Date:  2019-05-29       Impact factor: 5.349

Review 2.  Lyme carditis--diagnosis, treatment and prognosis.

Authors:  Norbert Scheffold; Bernhard Herkommer; Reinhard Kandolf; Andreas E May
Journal:  Dtsch Arztebl Int       Date:  2015-03-20       Impact factor: 5.594

3.  Intrathecally produced IgG and IgM antibodies to recombinant VlsE, VlsE peptide, recombinant OspC and whole cell extracts in the diagnosis of Lyme neuroborreliosis.

Authors:  Gerold Stanek; Lara Lusa; Katarina Ogrinc; Mateusz Markowicz; Franc Strle
Journal:  Med Microbiol Immunol       Date:  2013-12-23       Impact factor: 3.402

4.  Lyme Neuroborreliosis.

Authors:  Sebastian Rauer; Stefan Kastenbauer; Volker Fingerle; Klaus-Peter Hunfeld; Hans-Iko Huppertz; Rick Dersch
Journal:  Dtsch Arztebl Int       Date:  2018-11-09       Impact factor: 5.594

5.  Reply to Lacout et al., "Value of Patient Population Selection and Lyme Borreliosis Tests".

Authors:  Petr Kodym; Zuzana Kurzová; Dagmar Berenová; Dušan Pícha; Dita Smíšková; Lenka Moravcová; Marek Malý
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

6.  Subacute parkinsonism as a complication of Lyme disease.

Authors:  Guillaume Pisché; Meriam Koob; Thomas Wirth; Véronique Quenardelle; Ouhaïd Lagha-Boukbiza; Mathilde Renaud; Mathieu Anheim; Christine Tranchant
Journal:  J Neurol       Date:  2017-03-27       Impact factor: 4.849

Review 7.  [Choosing wisely recommendations in rheumatology : One year after their first publication].

Authors:  E Märker-Hermann; A J Voormann
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

8.  Comparison of Clinical Course and Treatment Outcome for Patients With Early Disseminated or Early Localized Lyme Borreliosis.

Authors:  Daša Stupica; Vera Maraspin; Petra Bogovic; Katarina Ogrinc; Rok Blagus; Tjaša Cerar; Franc Strle
Journal:  JAMA Dermatol       Date:  2018-09-01       Impact factor: 10.282

Review 9.  Clinical spectrum of Lyme disease.

Authors:  Jesus Alberto Cardenas-de la Garza; Estephania De la Cruz-Valadez; Jorge Ocampo-Candiani; Oliverio Welsh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-19       Impact factor: 3.267

Review 10.  Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: A Network Meta-analysis.

Authors:  Gabriel Torbahn; Heidelore Hofmann; Gerta Rücker; Karin Bischoff; Michael H Freitag; Rick Dersch; Volker Fingerle; Edith Motschall; Joerg J Meerpohl; Christine Schmucker
Journal:  JAMA Dermatol       Date:  2018-11-01       Impact factor: 10.282

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.